{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens antigen presentation, including expansion of the MHC-I peptidome in tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Vaccination-associated tumor priming aligns with improved outcomes during checkpoint blockade, including better survival in the retrospective human cohort.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized, and tumor-type plus treatment-history heterogeneity limits causal interpretation."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling appears mechanistically necessary for the sensitization effect.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, so mechanistic dependence should be prospectively validated clinically."
    },
    {
      "claim_id": "C04",
      "claim": "The sensitization effect is conditional, because single-agent arms and non-mRNA particle controls did not replicate durable benefit.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        },
        {
          "quote": "ICI-only treatment had limited activity in low-immunogenic baseline settings.",
          "line_ref": "L37"
        },
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        }
      ],
      "caveat": "Some model systems showed stronger effects than others, indicating context dependence and limiting broad generalization across all tumor settings."
    }
  ]
}